JCAR 015

Drug Profile

JCAR 015

Alternative Names: anti-CD19-CD28-zeta modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; anti-CD19/CD28/zeta modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; CD28-modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; JCAR 15; JCAR015

Latest Information Update: 03 Mar 2017

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Juno Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Mar 2017 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) due to incidences of severe neurotoxicity and deaths due to cerebral oedema, and Juno's strategic decision
  • 01 Mar 2017 Discontinued - Phase-II for Acute lymphoblastic leukaemia (Second-line therapy or greater) in USA (IV) due to incidences of severe neurotoxicity and deaths due to cerebral oedema, and Juno's strategic decision
  • 23 Nov 2016 Juno Therapeutics places voluntary clinical hold on the phase II ROCKET trial in Acute lymphoblastic leukaemia due to two cerebral oedema events
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top